Meeting
2016 ASCO Annual Meeting
HSD3B1 and resistance to androgen deprivation therapy in prostate cancer.
Authors
Jason W.D. Hearn
University of Michigan, Ann Arbor, MI
Jason W.D. Hearn , Ghada AbuAli , Chad A. Reichard , Chandana A. Reddy , Cristina Magi-Galluzzi , Kai-Hsiung Chang , Rachel Carlson , Laureano J Rangel , Kevin Reagan , Brian Davis , Jeffrey Karnes , Manish Kohli , Donald J Tindall , Eric A. Klein , Nima Sharifi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Epidemiology/Outcomes
Citation
J Clin Oncol 34, 2016 (suppl; abstr 5015)
DOI
10.1200/JCO.2016.34.15_suppl.5015
Abstract #
5015
Poster Bd #
272
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
HSD3B1 and resistance to androgen deprivation therapy in prostate cancer.
First Author: Jason W.D. Hearn
Poster
2015 Genitourinary Cancers Symposium
HSD3B1 and resistance to androgen deprivation therapy in prostate cancer.
First Author: Jason W.D. Hearn
Poster
2019 ASCO Annual Meeting
Outcomes of men with recurrent M0 prostate cancer who defer androgen deprivation therapy until metastasis.
First Author: Catherine Handy Marshall
Poster
2016 ASCO Annual Meeting
Development and validation of genomic signature to predict ADT treatment failure.
First Author: Jeffrey Karnes